AN IN-DEPTH ANALYSIS OF POLE ULTRAMUTATED ENDOMETRIAL CARCINOMA- REVIEW

POLE ultramutated endometrial carcinoma is characterized by a unique genetic profile with a high mutation burden due to alterations in the polymerase epsilon (POLE) gene.This review explores the distinctive clinicopathological features, prognosis, and therapeutic implications of this rare subset of endometrial cancer. POLE mutations confer a hypermutated state that may enhance immunogenicity and improve patient outcomes compared to other endometrial carcinoma variants. This type of carcinoma typically shows favorable prognostic factors, including reduced rates of myometrial invasion and lymphovascular space involvement, leading to better overall survival and disease-specific outcomes. The review also discusses the potential for targeted immunotherapeutic strategies, leveraging the high mutational load to improve response rates to treatment.Future challenges include the need for precise diagnostic tools to identify POLE mutation status accurately and the exploration of novel therapeutic avenues that could further enhance the management of patients with this promising yet challenging form of endometrial carcinoma.